UPDATE: Piper Jaffray Upgrades Osiris Therapeutics, Pull-Back Offers Attractive Entry Point

In a report published Wednesday, Piper Jaffray analyst Edward A. Tenthoff upgraded the rating on Osiris Therapeutics (NASDAQ: OSIR ) from Neutral to Overweight, and reiterated the $21.00 price target. In the report, Piper Jaffray noted, “In July, Osiris reported interim results on Grafix in Diabetic Foot Ulcers (DFUs) that